Five monoamine oxidase inhibitors (MAOI) were tested for a correlation between MAO blocking potency, the effect on somatotrophic hormone (STH) production and metabolic effects on the pituitary.
Mebanazine, N-acetyl-mebanazine and pargyline inhibited STH production, body weight gain and glucose-6-phosphate (G-6-P) dehydrogenase activity. MAOI which contain a hydrazine group (mebanazine and N-acetyl-mebanazine) also inhibited alkaline phosphatase activity as well as DNA and RNA formation in the pituitary, while pargyline, which contains an amino group, was inactive in these respects.
Iproniazid and norpargyline were inactive with regard to STH production, body-weight gain and metabolic activities of the pituitary: alkaline phosphatase activity, G-6-P dehydrogenase activity, and DNA and RNA content. This suggests a relation between the ability of an MAOI to inhibit STH production and inhibition of the phosphogluconate oxidative pathway.
Journal of Endocrinology is committed to supporting researchers in demonstrating the impact of their articles published in the journal.
The two types of article metrics we measure are (i) more traditional full-text views and pdf downloads, and (ii) Altmetric data, which shows the wider impact of articles in a range of non-traditional sources, such as social media.
More information is on the Reasons to publish page.
| Sept 2018 onwards | Past Year | Past 30 Days | |
|---|---|---|---|
| Full Text Views | 0 | 0 | 0 |
| PDF Downloads | 2 | 0 | 0 |
Online ISSN: 1479-6805
Print ISSN: 0022-0795
Strengthening biomedical communities
to advance science and health
CONTACT US
Bioscientifica Ltd | Starling House | 1600 Bristol Parkway North | Bristol BS34 8YU | UK
Bioscientifica Ltd | Registered in England no 3190519
